Canada has become the first member of the Group of Seven industrialised nations to approve generic versions of semaglutide — the active ingredient in the blockbuster weight-loss and diabetes drugs Ozempic and Wegovy — with lower-cost alternatives now rolling out to pharmacies across the country this month.
A Milestone for Affordable Weight-Loss Treatment
The approval marks a watershed moment in the global effort to make highly effective but expensive obesity medications accessible to a broader population. Generic semaglutide is expected to be significantly cheaper than the brand-name versions manufactured by Danish pharmaceutical giant Novo Nordisk, which can cost several hundred dollars per month even with insurance coverage in North America.
Canadian health authorities confirmed that several manufacturers have been cleared to produce and distribute the generic formulation. Pharmacies in major cities reported early demand was strong, with patients and healthcare providers alike eager to take advantage of the more affordable option.
Why the US Remains Without Generic Access
By contrast, American patients continue to wait. Novo Nordisk holds active patents on semaglutide in the United States that are not scheduled to expire for several years, meaning generic competitors cannot legally enter the US market under existing intellectual property law. Efforts by US lawmakers and advocacy groups to accelerate generic approval through patent reform have so far failed to advance through Congress.
The Weight-Loss Drug Revolution
Semaglutide drugs have transformed the treatment of obesity and Type 2 diabetes since their introduction, demonstrating in clinical trials that patients can lose a significant proportion of their body weight while on the medication. Demand has outstripped supply in many markets, driving up costs and leaving many patients unable to access treatment.
Public health advocates argue that the cost barrier represents a serious equity issue, given that obesity disproportionately affects lower-income populations who are least able to afford expensive brand-name medications. For the millions of Americans who have been prescribed or are considering semaglutide drugs, the Canadian approval serves as a reminder of the uneven global landscape in pharmaceutical access — and a preview of what lower prices could mean once US patents eventually expire.
